Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of GLPG CAR T-cell therapies
NL-OMON59167Phase 3Recruiting
- Sponsor
- Lakefront Biotherapeutics
- Start
- Sep 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of GLPG5301 in mature B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and multiple myeloma (MM), sponsored by Lakefront Biotherapeutics. Primary endpoints: Targeted adverse events, Related serious adverse events and 3 more. Started Sep 2024; status: recruiting.
02
Drugs
GLPG5301
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59167.